Summary
Edwards Lifesciences Corporation's (EW) 2004 10-K filing highlights a year of steady growth, with net sales increasing by 8.3% to $931.5 million. The company's core business in Heart Valve Therapy showed robust performance, with a 14.4% increase in sales driven by the adoption of its PERIMOUNT Magna valve. Critical Care products also saw an 8.4% sales increase, supported by market share gains in pressure monitoring. Financially, the company reported net income of $1.7 million, a significant decrease from the prior year, largely due to substantial charges related to acquisitions, particularly the $81 million in-process R&D for Percutaneous Valve Technologies (PVT). Despite this, Edwards Lifesciences continues to invest heavily in research and development, with a 9.3% of net sales allocated to R&D, focusing on percutaneous valve technologies and minimally invasive monitoring. The company's strong international presence, representing 55.3% of total sales, positions it well amidst global healthcare trends, though it also exposes it to currency exchange rate risks. Looking ahead, Edwards Lifesciences is focused on expanding its product offerings in heart valve repair and minimally invasive monitoring. The company's financial position remains solid with substantial liquidity and a diversified business model across key cardiovascular disease areas, providing a positive outlook for continued innovation and market leadership.
Key Highlights
- 1Net sales increased by 8.3% to $931.5 million in 2004, driven by strong performance in Heart Valve Therapy and Critical Care segments.
- 2Heart Valve Therapy sales grew 14.4%, largely due to the successful adoption of the PERIMOUNT Magna valve.
- 3Significant investment in R&D (9.3% of net sales) continues, with a focus on percutaneous valve technologies and minimally invasive critical care monitoring.
- 4Net income of $1.7 million was impacted by substantial charges, notably $81 million in in-process R&D from the PVT acquisition.
- 5International sales represented 55.3% of total revenue, underscoring the company's global market presence.
- 6The company acquired Percutaneous Valve Technologies, Inc. (PVT) and ev3, Inc.'s percutaneous mitral valve repair program, enhancing its development in transcatheter valve technologies.
- 7Edwards Lifesciences maintains a strong balance sheet with $48.9 million in cash and cash equivalents and $500 million in revolving credit facilities.